Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients
June 08, 2021 08:15 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased...
Silo Pharma Submits Application for NASDAQ up-listing
May 25, 2021 08:15 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, May 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased...
Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review.
May 13, 2021 08:15 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, May 13, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics
April 28, 2021 08:05 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, April 28, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ
April 22, 2021 08:05 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, April 22, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today...
Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology
April 07, 2021 08:01 ET
|
Silo Pharma, Inc.
Agreement to explore the use of Silo Pharma’s Novel Peptide Englewood Cliffs, NJ, April 07, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company...
Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis
March 04, 2021 08:44 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, March 04, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC QB: SILO), a developmental stage biopharmaceutical company, today announced that it has executed an exclusive option...
Silo Pharma to Present at Proactive's One2One Virtual Investor Forum
February 23, 2021 08:15 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS
February 18, 2021 08:15 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds
February 10, 2021 08:45 ET
|
Silo Pharma, Inc.
Silo Pharma to pursue additional strategic partnerships and intellectual property acquisitions in the psychedelic medicine space Englewood Cliffs, NJ, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Silo...